1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research Accelerator for Follicular Lymphoma (RAFL) Program - Translational Awards is sponsored by The Leukemia & Lymphoma Society (LLS) and Institute for Follicular Lymphoma Innovation (IFLI). These grants aim to support clinical and/or biological research in follicular lymphoma, with the goal of funding researchers planning to conduct a clinical trial by year three of the grant.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
New $20 Million Research Funding Program Aims to 'Accelerate a Cure' for Follicular Lymphoma The Leukemia & Lymphoma Society and the Institute for Follicular Lymphoma Innovation commit $20 million to jointly fund follicular lymphoma research. RYE BROOK, N. Y.
, June 3, 2024 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Institute for Follicular Lymphoma Innovation (IFLI) today announce a new partnership on a $20-million initiative to fund research in follicular lymphoma, the most common slow-growing non-Hodgkin's lymphoma.
The goal of the initiative, which will be named the Research Accelerator for Follicular Lymphoma (RAFL) Program, is to provide researchers with funding to identify how follicular lymphoma develops and create new therapies that better control and cure this blood cancer. "Cutting-edge technologies are redefining our approach to follicular lymphoma, setting new standards in both understanding and treatment," says Michel Azoulay , M. D.
, MBA, the Institute for Follicular Lymphoma's Chief Medical Officer. "The RAFL partnership, a collaborative effort between IFLI and LLS, is empowering researchers to lead the charge in breakthrough innovations." LLS and IFLI are committing to fund three types of competitive grants for selected innovative research programs in follicular lymphoma: a Synergistic Team Award, Translational Awards and Innovation Awards.
Synergistic Team Award —This multi-investigator grant is designed to support a coordinated, focused and significant effort to understand the biology of follicular lymphoma and develop effective treatments for the disease. Multiple investigators from the same or different institutions working collaboratively will be eligible for this grant. Translational Awards — These grants aim to support clinical and/or biological research.
The goal is to award these grants to researchers planning to conduct a clinical trial by year three of the grant. Innovation Awards — These grants are intended to support projects that identify better ways to understand or treat follicular lymphoma.
These three grants are expected to be awarded over two different rounds: the Synergistic Team Award and two of the four Translational Awards would be conferred during the first round and the remaining Translational Awards and Innovation Awards would be granted during the second round.
"This partnership between LLS and IFLI is a testament to our commitment to joining forces with like-minded organizations that share our goal of accelerating innovation that improves the lives of blood cancer patients," says Lee Greenberger , Ph. D. , Chief Scientific Officer at The Leukemia & Lymphoma Society.
The RAFL Program expects to begin accepting grant applications by July 1, 2024 , with the review process taking place in spring 2025. About The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society® (LLS) is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families.
LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Founded in 1949 and headquartered in Rye Brook , NY, LLS has regions throughout the United States and Canada . To learn more, visit www.
LLS. org . Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.
m. to 9 p. m.
ET . LLS stands out among brands around the world for its relevancy, cultural impact, ingenuity, and mission impact. About Institute for Follicular Lymphoma Innovation The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma.
IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of follicular lymphoma (FL), and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropy investments to achieve its innovation goals.
IFLI aims to promote collaboration, and enable the exchange of knowledge and expertise among researchers and institutions working on different aspects of FL research. Learn more at i-fli. org .
LLS — Ryan McDonald , [email protected] IFLI — Klara Sol Sigurdardottir , [email protected] SOURCE The Leukemia & Lymphoma Society more press release views with
According to the current listing, eligibility includes: Researchers are eligible. These grants are for clinical and/or biological research in follicular lymphoma. Confirm the full requirements in the official notice before applying.
Research Accelerator for Follicular Lymphoma (RAFL) Program - Translational Awards is funded by The Leukemia & Lymphoma Society (LLS) and Institute for Follicular Lymphoma Innovation (IFLI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
The FY2026 Bus Safety, Accessibility, and Innovation Research Program closes September 28. Universities, agencies, and startups are all eligible to lead — but every team must include a transit vehicle manufacturer in a prominent role, and FTA already cancelled a nearly identical NOFO in 2024 without making a single award.
Read articleThe FY2026 Agriculture Innovation Center Demonstration Program posted September 9 with a January 31, 2027 deadline. It is the first competition under a rule codified in 2024, the award floor is $600,000, and the single most common way to lose is to upload your application to Grants.gov.
Read articleThe Public Wireless Supply Chain Innovation Fund started at $1.5 billion for open RAN. Congress rescinded $850 million, NTIA canceled Round 3, and what remains is a $53 million final round pointed at AI-native radio access networks — with a $25 million per-project ceiling, a mandatory 50 percent cost share, and rolling awards beginning this fall.
Read article